$CRVS Any ideas? . Corvus launches Angel Pharma, a $106M China-focused subsidiary (release) California oncology play Corvus Pharmaceuticals launched a wholly-owned subsidiary focused on China. Called Angel Pharmaceuticals, the $106 million unit came to life with investments from local CRO giant Tigermed, Betta Pharma, Hisun Pharma and Zhejiang Puissance Capital, and three of Corvus’ clinical-stage candidates and a preclinical BTK inhibitor.